Zentalis Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 1.99 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 188.40M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian ...